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These studies indicate STAT3 siRNA could be a useful 
therapeutic tool for the treatment of colon cancer.
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INTRODUCTION
Signal transducers and activator of  transcription, STATs, are 
a family of  transcription factors that transmit signals from 
cell surface receptors directly to the nucleus[1]. Activation 
of  all the STAT proteins is caused by phosphorylation of  
a single tyrosine residue that leads to dimerization via an 
intermolecular SH2 phosphotyrosine interaction[2-5]. The 
dimerized STATs then translocate to the nucleus where they 
regulate gene expression by binding directly to high affinity 
DNA binding sites or by associating with other transcription 
factors[6-11]. They play a critical role in mediating cytokine 
and growth factor signaling involved in cell growth, 
differentiation and survival[12-14]. Among the seven members 
of  the mammalian STAT family, STAT3 has been the most 
strongly implicated in oncogenesis[15]. 
Some studies showed that constitutively activated 
STAT3 is found in a wide variety of  human tumors 
including multiple myelomas, breast, ovarian, prostate, and 
head and neck tumors[16-18]. Inhibition of  STAT3 signaling 
with either dominant negative or antisense oligonucleotides 
against STAT3 suppresses the transformation process in 
some tumors[19]. Recent studies have shown that treatment 
of  tumor cells with inhibitors of  STAT signaling results 
in decreased cell viability and induction of  apoptosis[20]. 
Together these findings demonstrate that STAT3 signaling 
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Abstract
AIM: To investigate the roles and mechanism of signal 
transducer and activator of transcription 3 (STAT3) in 
invasion of human colon cancer cells by RNA interference. 
METHODS: Small interfering RNA (siRNA) targeting 
Signal transducer and activator of transcription 3 
(STAT3) was transfected into HT29 colon cancer cells. 
STAT3 protein level and DNA-binding activity of STAT3 
was evaluated by western blotting and electrophoretic 
mobility shift assay (EMSA), respectively. We studied the 
anchorage-independent growth using colony formation in 
soft agar, and invasion using the boyden chamber model, 
anoikis using DNA fragmentation assay and terminal 
deoxynucleotidyltransferase-mediated dUTP nick-end 
labeling (TUNEL), respectively. Western blot assay was 
used to observe the protein expression of Bcl-xL and 
survivin in colon cancer HT29 cells.
RESULTS: RNA interference (RNAi) mediated by siRNA 
leads to suppression of STAT3 expression in colon cancer 
cell lines. Suppression of STAT3 expression by siRNA 
could inhibit anchorage-independent growth, and invasion 
ability, and induces anoikis in the colon cancer cell line 
HT29. It has been shown that knockdown of STAT3 
expression by siRNA results in a reduction in expression of 
Bcl-xL and survivin in HT29 cells.
CONCLUSION: These results suggest that STAT3 siRNA 
can inhibit the invasion ability of colon cancer cells 
through inducing anoikis, which antiapoptotic genes 
survivin and Bcl-xL contribute to regulation of anoikis. 
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plays a critical role in both the transformation process and 
tumor progression in some types of  cancer. 
Recent reports showed that STAT3 has a significant 
association with tumor invasion and metastasis of  a few 
cancers[21-25]. In renal cell carcinoma, the positive rate of  
the expression of  p-STAT3 correlated well with the depth 
of  tumor invasion and with metastasis[21]. In colorectal 
adenocarcinoma, p-STAT3 protein was significantly 
correlated with the depth of  tumour invasion, venous 
invasion, lymph node metastasis, and increasing stages 
of  the Dukes' classification[25]. In addition, blockade of  
activated STAT3 via ectopic expression of  dominant-
negative STAT3 significantly could suppress angiogenesis, 
tumor growth, and metastasis in pancreatic cancer[26].
Together these findings demonstrate that STAT3 activation 
might be a new potential target for therapy of  human 
cancer metastasis. Recently it has been shown that STAT3 
is constitutively activated in colon cancer[25], however, the 
role and mechanism of  STAT3 signaling in metastasis of  
colon cancer remains elusive.
Colorectal cancer is the third most common malignant 
neoplasm worldwide[27] and the second leading cause of  
death due to cancer[28]. Despite recent advances in diagnostic 
and therapeutic measures, the prognosis of  colorectal 
cancer patients with distant metastasis still remains poor. 
Liver metastasis is a major cause of  morbidity and mortality 
in patients with colon cancer. Colorectal liver metastasis 
is associated with a very poor prognosis; most patients 
die within 2 years of  diagnosis despite the availability of  
numerous therapies. To improve the choice of  therapeutic 
strategy, it is critical that the mechanism of  invasion and 
metastasis of  colon cancer be clarified. Here we will show 
that knockdown of  STAT3 expression by siRNA inhibit 
invasion ability and reduces anoikis resistance in colon 
cancer cells.
MATERIALS AND METHODS
Human colon cancer cell lines  
The human colon cancer cell lines HT29, SW620 and 
SW480 were obtained from the Institute of  Cell Biology, 
Shanghai, China. All cancer cells were cultured in RPMI 
1640 supplemented with 10% fetal calf  serum (FCS). These 
studies were carried out with Medical Ethical Committee 
approval of  Jiangsu University.
STAT3 siRNA and siRNA transfections 
A double stranded siRNA oligonucleotide against STAT3 
(5'-AACAUCUGCCUAGAUCGGCUAdTdT-3'; 3'-dTd
TGUAGACGGAUCUAGCCGAU-5') was designed and 
synthesized by Dharmacon Research, Inc. Oligofectamine 
(Invitrogen, Inc.). In brief, 1 d prior to transfection, cancer 
cells were seeded, without antibiotics, into a 24 well plate, 
1 × 105 cells/well, corresponding to a density of  60%-70% 
at the time of  transfection. There were the following groups: 
siRNA groups: cells transfected with siRNA at different 
doses; control groups: cells treated with oligofectamine 
alone without siRNA. All transfections were performed in 
triplicate for each time point. At different times after the 
beginning of  the transfection period, all cells were harvested 
and the following assays were performed.
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Western blot analyses
HT29 cells were harvested and lysed in a buffer containing 
10 mmol/L Tris-HCl (pH 8.0), 150 mmol/L NaCl, 1% 
NP40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mmol/L 
EDTA (pH 8.0), 2 mmol/L phenylmethylsulfonyl 
fluoride, 2 μg/mL aprotinin, 2 μg/mL leupeptin, and 
1 mmol/L Na3VO4. For western blot analyses, 30 μg of  
total extracted proteins were applied per lane before SDS-
PAGE. Following transfer to nitrocellulose membranes, 
protein expression levels were detected using polyclonal 
anti-STAT3 (Santa Cruz, CA), anti- phospho-STAT3, anti-
Bcl-xL and anti-survivin (Alpha Diagnostics International, 
TX). The expression of  b-actin (Sigma-Aldrich, MO) was 
used as a normalization control for protein loading.
Electrophoretic mobility shift assay (EMSA) for STAT3-
DNA binding activity
The STAT3-DNA binding activity was assessed by EMSA 
using the nuclear extract from the three cell lines. The 
sense strand that binds activated STAT3 protein was 
5'-TCGACATTTCCCGTAAATC-3'. Double-stranded 
oligonucleotide was end-labeled with [γ-32P] ATP using a 
T4 polynucleotide kinase according to the manufacturer's 
instruction. The final concentration of  probe was 
1.75 pmol/L. The labeled probes were then purified by 
G-25 spin columns. One microliter of  32P-labeled STAT3 
oligonucleotide was added to each reaction. For STAT3 
specific tests, a 150-fold unlabeled STAT3 probe was 
applied as a competitor. The final volume of  reaction was 
20 μL, including 10 μg of  nuclear extract and 5 × binding 
buffer. The reactions were placed on ice for 30 min. 
The 45 g/L nondenaturing acrylamide gel was pre-run 
in 1 × TBE buffer at 25 mA for 60 min. After loading 
of  the samples, the gel was run at room temperature in 
1 × TBE buffer at 25 mA for 90 min. The gel was dried on 
a gel dryer, then exposed to X-ray film overnight at -80℃ 
with intensifying screen. The protein-DNA complex was 
detected by autoradiography. The Quantity one software 
was used to analyze the scanned EMSA gel bands.   
Anchorage-independent growth assay
For the anchorage-independent growth experiments, 
HT29 cells (8 × 103 cells/well) were seeded in 0.3% Difco 
Bactoagar (Difco, MI) supplemented with complete culture 
medium. This suspension was layered over 0.5 mL of  
0.8% agar-medium base layer in 24 multiwell cluster dishes 
(Becton Dickinson, Italy). After 15 d, the colonies were 
stained with nitroblue tetrazolium, and colonies larger 
than 50 μm were acquired with a micro-Scopeman camera 
system (Moritex Europe Ltd, Italy) and analyzed with 
an Image-Pro Plus (Media Cybernetics, MD) computer 
program.
Cell invasion assay
Cell invasion assay was performed using Boyden chambers 
and 8 μm pore size polyvinylpyrrolidone-free polycarbonate 
fi lters coated with 25 μg/filter Matrigel (Beckton 
Dickinson). After transfection for 48 h, Sub-confluent 
HT29 control or HT29 STAT3 cell lines were harvested by 
a mild trypsinization, washed twice with Cellect medium 
and counted. Cells (2 × 105 viable cells/sample) were 
allowed to invade Matrigel toward 10% FBS/Cellect 
at 37℃, 5% CO2 for 3 h. At the end of  the assay, cells 
on the lower surface of  the filter were fixed in ethanol, 
stained with hematoxylin, and 10 random fields/filter 
were counted at 200 × magnification. Data represent the 
average of  three experiments, all performed in triplicate.
Induction of anoikis
To prevent cell adhesion, 6-well plates were coated 
with a solution of  polyhydroxyethylmethacrylate (poly-
HEMA,Sigma-Aldrich), dissolved at 10 mg/mL in 
ethanol[29,30]. To coat 6-well plates, 3 mL of  poly-HEMA 
solution was added to each well. Plates were kept at 37℃ 
for at least 3 d until the solvent had completely evaporated. 
To induce anoikis, 48 h after transfection, cells were 
harvested and moved to plates coated with poly-HEMA. 
1 × 106 resuspended cells were cultured in DMEM medium 
containing 15% FCS for 12 h on poly-HEMA-coated 
dishes at 37℃ and 5% CO2. Subsequently, cells were gently 
recovered and submitted to apoptosis detection assays. 
Terminal deoxynucleotidyltransferase-mediated dUTP
nick-end labeling (TUNEL) assay
The TUNEL assay was performed according to a previous 
report[31]. Apoptosis index (AI) determination: apoptosis 
cells/total cell × 100%.   
DNA fragmentation assay
For demonstration of  internucleosomal DNA fragme-
ntation, after cells were plated in 6-well plates coated with 
poly-HEMA for different times, the cells were harvested, 
washed with PBS solution at 4℃, and suspended in lysis 
buffer (10 mmol/L Tris-HCl pH 7.5, 10 mmol/L EDTA, 
and 0.2% Triton × 100). After incubation for 15 min at 
4℃, samples were centrifuged at 13 000 × g for 10 min at 
4℃. The supernatant containing the fragmented DNA 
was precipitated with NaCl 0.5 mol/L and 1 volume 
of  isopropanol for at least 1 h at -70℃. Samples were 
centrifuged at 13 000 × g for 10 min at 4℃, and the pellet 
was washed once with 70% ethanol, and air-dried. The 
precipitates were dissolved in 10 μL TE-RNase (0.1 mg/mL) 
and incubated at 37℃ for 30 min. Finally, the samples were 
electrophoresed through a 1% agarose gel.
Statistical analysis
Statistical significance of  results was evaluated by SSPS10.0 
software. All results with P values ≤ 0.05 were considered 
significant.
RESULTS
Effects of siRNA on the expression and DNA binding
activity of STAT3 in the colon cancer cell line HT29
To inhibit STAT3 expression in colon cancer cells, we 
used the RNAi method adapted for mammalian cell 
culture by Elbashir et al[32]. A number of  21 bp double 
stranded RNAs to human STAT3 were synthesized and 
tested for their ability to knockdown STAT3 expression 
in colon cancer HT29 cells. The human colon cancer cell 
line HT29, harboring activated STAT3, was transfected 
with STAT3 siRNA using oligofectamine. Twenty-four 
and 72 h after transfection, the protein levels and DNA-
binding activities of  STAT3 were measured by western 
blot and EMSA, respectively. Transfection of  cells with 
STAT3 siRNA (Figure 1A) resulted in a highly significant 
and reproducible decrease in STAT3 expression levels as 
judged by western blotting (Figure 1B). Figure 1A shows 
that STAT3 siRNA diminished STAT3 protein compared 
with control groups, accompanied by a significant decrease 
in STAT3 DNA-binding activity (Figure 1B). STAT3 
knockdown by siRNA was found to be time dependent 
with the maximum effect achieved at 48-72 h of  siRNA 
treatment (Data not shown). 
STAT3 RNAi inhibits anchorage-independent growth in
colon cancer cells 
Next we evaluated the biological effects of  STAT3 
suppression in colon cancer HT29 cells by using several 
different types of  assays. Colony formation in soft agar is 
a property closely associated with malignancy[33]. Figure 2 
shows that treatment with STAT3 siRNA induced 
significant anchorage-independent growth inhibition in a 
dose-dependent manner. 
STAT3 RNAi suppresses invasion in colon cancer cells
Next, we assessed whether STAT3 suppression might 
decrease the ability of  cancer cells to invade the extracellular 
matrix. HT29 cancer cells were subjected to cell invasion 
assays, by using Boyden chambers and 8 μm pore size filters 
coated with Matrigel. Compared with the control group, 
HT29 cells transfected with siRNA exhibited a scarce ability 
to cross Matrigel (Figure 3). This difference was statistically 
significant as compared with control groups (P < 0.01). 
Effects of STAT3 suppression on anoikis
To explore the molecular mechanisms of  invasion of  
colon cancer, anoikis was studied. To investigate the effect 
of  STAT3 siRNA on anoikis, HT29 cells were subjected to 
























Figure 1  A: Expression of STAT3 protein in HT29 cells; B: STAT3 DNA-binding 
activity by EMSA in HT29 cells. 1: Control; 2, 3, 4: siRNA 2, 4, 8 nmol/L.
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all cells were removed to plates seeded in poly-HEMA 
for 12 h. TUNEL and DNA ladder were performed 
to evaluate the anoikis of  HT29 cells. There was little 
apoptosis in all cancer cells in attached culture. When in 
a suspended culture, there was significant apoptosis in 
cancer cells treated with STAT3 siRNA. A significantly 
higher percentage of  apoptotic index was observed in 
STAT3 siRNA treated cells than in only oligofectamine 
treated cells (Figure 4A). Consistent with this observation, 
agarose electrophoresis analysis of  HT29 cancer cell 
extracts showed that there was DNA ladder in cells treated 
with STAT3 siRNA (Figure 4B). Together these data 
indicate that siRNA-mediated suppression of  the STAT3 
gene reduces resistance to anoikis of  HT29 cells.
Knockdown of STAT3 expression down regulates survival 
genes
Recent data indicate that some genes, especially anti-
apoptotic genes, contribute to regulation of  anoikis[34].
Constitutive activation of  STAT3 induces the expression 
of  a number of  anti-apoptotic genes including Bcl-xL, a 
member of  the Bcl-2-family of  anti-apoptotic genes[20,35], 
and survivin, a member of  the IAP, inhibitors of  apoptotic 
proteins family[36]. Moreover, both of  these genes are 
expressed in colon cancer[37,38]. In order to determine 
whether these two genes might be involved in the STAT3 
mediated anoikis resistance in colon cancer, western blot 
analyses were performed to examine the expression levels 
of  the two genes. Western blot analysis showed that Bcl-xL 
and survivin protein levels were drastically reduced upon 
treatment with STAT3 siRNA. Thus, these data show 
that STAT3 regulates anoikis of  at least two distinct 
antiapoptotic genes in colon cancer HT29 cell (Figure 5).
DISCUSSION
STAT3 is activated by a number of  cytokines and growth 
factors and has diverse functions during embryogenesis 
and early development[12-14]. Some studies showed that 
there is persistent activation of  STAT3 in a number of  
human solid tumors including colon cancer[16-18]. Elevated 
STAT3 activity has been shown to render cells resistant to 
apoptosis, and inhibition of  STAT3 signaling in a number 
of  tumor cell lines with some ways causing a decrease 
in cell viability and subsequent apoptosis[16,17]. Lots of  
studies have demonstrated that the transformation process 
induced by diverse oncogenic protein tyrosine kinases 
is dependent on STAT3 activation[18,39,40]. Recently it has 
been shown that STAT3 is constitutively activated in colon 
cancer. However, the relationships of  STAT3 with invasion 
and metastasis in colon cancer cells remain unclear.  
In order to determine the role of  STAT3 in colon 
cancer directly, we have used RNAi to specifically knock 
down the expression of  STAT3, studied the effects of  
anchorage-independent growth and invasion in the colon 
cancer cell line HT29. SiRNAs are short oligonucleotides 
of  21-23 nucleotides in length that can be used in vitro to 
produce sequence specific gene silencing of  mammalian 
cells[32]. It has been shown that siRNAs can be used 
effectively in vivo to suppress gene expression in adult 
mice[41,42]. SiRNAs can be directly introduced into the CNS 
to reduce endogenous gene expression[43]. Transfection of  
colon cancer HT29 cells with STAT3 siRNA resulted in 
colonies forming membranes with reduced biochemical 
changes indicative of  invasion. In addition, consistent with 
the results from HT29 cancer cell, SW480 and SW620 
cancer cells transfectd with the STAT3 siRNA led to a 
decrease of  both invasion and anchorage-independent 
Figure 2  Effects of STAT3 siRNA on anchorage-independent growth of HT29 
cells. It shows that treatment with STAT3 siRNA inhibit anchorage-independent 
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Figure 4  Effects of STAT3 siRNA on anoikis of human colon cancer cell line 
HT29. A: AI (Apoptosis index) induced with STAT3 siRNA in HT29 cells; B: DNA 
ladder by STAT3 siRNA in HT29 cells. 1: Control; 2, 3, 4: siRNA, 2, 4, 8 nmol/L.
A B
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growth. These results are similar to reports previously 
observed with AG490 inhibiting STAT3 in pancreatic 
cancer cells [34]. All data suggest that STAT3 down-
regulation by RNAi inhibit metastasis of  human cancer 
cell in vitro.
The metastasis and invasion of  cancer cells were 
involved in a lot of  mechanisms. Anoikis resistance was 
thought to be high. Anoikis is a peculiar form of  apoptosis 
that is induced by disruption of  the interactions between 
epithelial cells and extracellular matrix[29]. Induction of  
apoptosis upon loss of  anchorage has been termed anoikis 
(Greek for homelessness)[30]. Anoikis can be considered 
as a safety program for maintaining normal cell and tissue 
homeostasis, which prevents survival and reattachment 
of  detached cells to new matrices at inadequate locations. 
Anoikis has been suggested to act as a physiological barrier 
to metastasis; resistance to anoikis may allow survival of  
cancer cells during systemic circulation, thereby facilitating 
secondary tumour formation in distant organs. Gaining 


















Figure 5  Knockdown of STAT3 expression downregulates Bcl-xL and survivin 
protein level in the HT29 human colon cancer cell line. A: Inhibition of transfection 
with STAT3 siRNA on Bcl-xL expression of colon cancer HT29 cell; B: Suppression 






























432        ISSN 1007-9327       CN 14-1219/R     World J Gastroenterol         January 21, 2008    Volume 14     Number 3
t /h
t /h
is a hallmark of  oncogenic transformation. For these 
experiments, cells are usually seeded in tissue culture dishes 
that are coated with poly-HEMA, which does not allow 
cells to attach by preventing matrix deposition. Tumor 
cells are usually resistant to anoikis[30]. Our results here 
showed that, in attached culture, neither control cells nor 
transfected cells exhibited significant apoptosis, suggesting 
HT29 cells are resistant to anoikis. When seeded in poly-
HEMA plates, compared to the control group, there were 
significant signs of  apoptosis in cancer cells treated with 
STAT3 siRNA. It was shown that clear DNA ladder, the 
augmented the apoptosis index. These results suggest that 
STAT3 siRNA induces anoikis of  HT29 colon cancer cells.
One mechanism by which STAT3 participates in 
tumorigenesis is by inhibiting apoptosis through the 
induction of  anti-apoptotic genes such as Bcl-2, Bcl-xL, 
and Mcl-1[18]. STAT3 responsive elements are found in 
the promoter region of  these genes, suggesting that they 
are directly regulated by STAT3[16,36]. Interestingly, some 
reports showed that some anti-apoptotic genes regulate 
anoikis. Biochemical studies have shown that Bcl-xL, a 
member of  the Bcl-2 family of  proteins, induce anoikis of  
some cancer cells[34,45], and we have found survivin gene 
is overexpressed in gastric cancer and survivin siRNA 
reduced the resistance of  anoikis of  gastric cancer cells 
(data not shown). In the present study, we have found 
that both Bcl-xL and survivin are expressed in HT29 
cells. Treating HT29 cells with STAT3 siRNA significantly 
reduces expression levels of  both of  these genes. These 
findings suggest that induction of  Bcl-xL and/or survivin 
gene by constitutively activated STAT3 contributes to 
regulating anoikis of  colon cancer cells.
Data presented in this paper are consistent with the 
growing body of  evidence suggesting STAT3 may be an 
ideal therapeutic target in tumors including colon cancer. 
We are the first to report that STAT3 siRNA can suppress 
invasion of  colon cancer through inducing anoikis. These 
results suggest that siRNA may become a useful clinical 
tool in the future. Since STAT3 signaling is important for 
the survival of  a number of  human tumors, STAT3 siRNA 




Some reports showed that STAT3 has a significant association with tumor invasion 
and metastasis of a few of cancers, however, the role and mechanism of STAT3 
signaling in metastasis of colon cancer remain elusive. 
Research frontiers
Induction of apoptosis upon loss of anchorage has been termed anoikis, and anoikis 
has been suggested to act as a physiological barrier to metastasis. Here we will 
show that knockdown of STAT3 expression by siRNA inhibit invasion ability by 
reducing the resistance anoikis in colon cancer cells. In addition, down-regulation 
of Bcl-xL and/or survivin by STAT3 siRNA might play an important role in inducing 
anoikis in human colon cancer cell. 
Innovations and breakthroughs
The paperwork showed that that STAT3 siRNA can inhibit invasion ability of colon 
cancer cells through inducing anoikis, and suppression of Bcl-xL and/or survivin by 
STAT3 siRNA might contribute to regulation of anoikis of human colon cancer cell. 
Applications 
Here we will show that knockdown of STAT3 expression by siRNA inhibits invasion 
ability and reduces the resistance anoikis in colon cancer cells. The paper would 
help to clarify the mechanism of invasion and metastasis of colon cancer and 
improve the choice of therapeutic strategy.
Terminology
Anoikis (Greek for homelessness) is a peculiar form of apoptosis that is induced 
by disruption of the interactions between epithelial cells and extracellular matrix.
Peer review
This is an interesting paper investigating the in vitro effect and mechanisms of 
STAT3 siRNAs in a colorectal cancer (CRC) cell line. The main finding of the study 
was that STAT3 siRNA can inhibit the invasion ability of colon cancer cells through 
inducing anoikis, in addition antiapoptotic genes survivin and Bcl-xL may contribute 
to regulation of anoikis. 
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